Form 4: Director Jean-Pierre Bizzari Trades ADC Therapeutics Shares

Jean-Pierre Bizzari, a Director at ADC Therapeutics SA, reported transactions involving restricted stock units and common shares.

Summary

• Director Jean-Pierre Bizzari acquired 45,000 restricted stock units (RSUs) on June 1, 2026, as an annual grant under the Issuer's 2019 Equity Incentive Plan for his services.
• These RSUs vest on the earlier of one year from the grant date or the 2027 Annual Meeting of Shareholders, contingent on continued service.
• Each RSU represents a contingent right to receive one share of ADC Therapeutics SA's common stock.
• On June 3, 2026, 12,600 common shares were withheld by the Issuer to cover tax obligations related to the vesting of previously granted restricted share units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily detailing routine equity grants and tax-related share withholdings for a director, with no significant new financial information or strategic shifts.

Positives

• Director Jean-Pierre Bizzari received an annual grant of 45,000 restricted stock units, indicating continued compensation and incentive for service.
• The RSUs are structured to vest over time, aligning the director's interests with the company's long-term performance and continued service.

Negatives

• 12,600 common shares were withheld to cover tax obligations, representing a reduction in the net shares received by the reporting person.

Risks

• The vesting of RSUs is subject to the Reporting Person's continued service to the Issuer, implying a risk of forfeiture if service is terminated before vesting.
• The value of the RSUs is tied to the performance of ADC Therapeutics SA's common stock, meaning their value could decrease if the stock price declines.

Future Outlook

The restricted stock units granted to Jean-Pierre Bizzari are set to vest on the earlier of one year from the grant date or the date of the 2027 Annual Meeting of Shareholders, provided his service to the Issuer continues.

Industry Context

StockSavvy.ai notes that the reporting of equity grants and tax withholdings via Form 4 is a standard disclosure for directors and officers in the biotechnology and pharmaceutical sector, reflecting common compensation practices and regulatory requirements.

Stakeholder Impact

• Shareholders: The transaction reflects standard director compensation practices and does not immediately impact share count or company financials in a significant way.

Next Steps

• Continued service by Jean-Pierre Bizzari to the Issuer.
• Vesting of restricted stock units on the earlier of one year from grant date or the 2027 Annual Meeting of Shareholders.

Key Dates

Keywords

Form 4, SEC Filing, ADC Therapeutics SA, ADCT, Jean-Pierre Bizzari, Director, Restricted Stock Units, RSUs, Equity Incentive Plan, Stock Transaction, Beneficial Ownership